https://www.selleckchem.com/products/mz-1.html
Careful patient selection plays a crucial role in avoiding overtreatment and further increases survival rates in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal cancer (CRC) with peritoneal metastases (PM). The clinical and molecular factors influencing survival in patients who had undergone CRS with HIPEC between January 2015 and December 2018 were analyzed. Sixty-six patients underwent CRS with HIPEC during the study period. The median overall survival (OS) was 36 month
Aimer
Commentaire
Partagez
